Three Novel Synthetic THC Analogs Identified in European Consumer Products
Researchers identified three never-before-seen semisynthetic THC analogs sold as "CB9," "tresconol," and "CBx" in the European market, none of which have safety data.
Quick Facts
What This Study Found
Products marketed under invented cannabinoid names contained novel THC analogs that have never been found in cannabis plants and lack any toxicological data. The compounds cannot be identified using standard forensic methods without advanced spectroscopic techniques.
Key Numbers
Three novel compounds identified: [2-(E)-propen-1-yl]-delta8-THC-acetate from "CB9," [2-propen-2-yl]-delta9-THC from "tresconol," and [2-propen-2-yl]-delta8-THC from "CBx." None have existing spectroscopic or chromatographic reference data.
How They Did This
Mass spectrometry and nuclear magnetic resonance spectroscopy were used to characterize compounds isolated from three commercial products in the European market.
Why This Research Matters
Consumers are buying products with made-up cannabinoid names, unaware they contain novel synthetic compounds with unknown safety profiles. Standard drug testing cannot detect these substances.
The Bigger Picture
As regulators ban specific cannabinoids like HHC, manufacturers create novel analogs to stay ahead of regulations. This cat-and-mouse dynamic echoes the 2015 synthetic cannabinoid crisis and poses similar public health risks.
What This Study Doesn't Tell Us
Analytical chemistry study only; no toxicological or pharmacological data on these compounds. Limited to products available in the European market.
Questions This Raises
- ?What are the pharmacological effects and safety profiles of these novel compounds?
- ?How widespread are they across consumer markets?
- ?Can rapid screening methods be developed?
Trust & Context
- Key Stat:
- 3 novel THC analogs with zero safety data sold openly in European markets
- Evidence Grade:
- Analytical chemistry identification study; establishes existence of novel compounds but provides no safety or efficacy data.
- Study Age:
- 2025 study identifying products currently on the market
- Original Title:
- Identification of Three Novel Tetrahydrocannabinol Analogs in the European Market.
- Published In:
- Drug testing and analysis, 17(9), 1594-1600 (2025)
- Authors:
- Dadiotis, Evangelos, Mpakaoukas, Sotiris, Mitsis, Vangelis, Melliou, Eleni, Magiatis, Prokopios
- Database ID:
- RTHC-06287
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Are these products legal?
They exist in regulatory gray zones. Manufacturers create novel analogs specifically to evade existing bans on substances like HHC. Legality varies by jurisdiction.
Are they safe?
Unknown. These compounds have never been tested in humans or animals. They have no established safety profiles and cannot be detected by standard drug testing.
Read More on RethinkTHC
- 420-sober-survival-guide
- CBT-cannabis-recovery
- THC-purity-potency-label-meaning
- cannabis-relapse-cycle-pattern
- cold-turkey-vs-taper-quit-weed
- dab-concentrate-addiction-withdrawal
- dating-sober-after-quitting-weed
- delta-8-addiction-withdrawal
- edible-addiction-withdrawal-different
- edibles-psychosis-emergency-room
- exercise-quitting-weed-anxiety-brain
- grieving-quitting-weed-loss
- healthiest-way-to-consume-cannabis
- help-someone-quit-weed
- how-cannabis-products-made-concentrates-edibles
- how-to-quit-weed
- journaling-weed-withdrawal
- laced-weed-fentanyl-contaminated-vape
- legal-weed-vs-street-weed-quality-safety
- marijuana-anonymous-SMART-recovery-compare
- meditation-mindfulness-weed-withdrawal
- partner-still-smokes-weed
- partner-still-smokes-weed-quitting
- pink-cloud-sobriety-cannabis
- quit-weed-cold-turkey
- quit-weed-or-cut-back-which-is-better
- quit-weed-regret-went-back
- quitting-dabs-withdrawal
- quitting-edibles-withdrawal
- quitting-weed-20s
- quitting-weed-30s
- quitting-weed-after-years
- quitting-weed-during-crisis-divorce-job-loss
- quitting-weed-exercise
- quitting-weed-grief-loss-coping
- quitting-weed-legal-state
- quitting-weed-success-stories
- quitting-weed-triggers-environment
- relapsed-smoking-weed-what-to-do
- relapsed-weed
- sativa-vs-indica-difference-myth
- should-i-quit-weed
- sober-music-festival-concert-without-weed
- supplements-weed-withdrawal
- telling-friends-quitting-weed
- weed-potency-withdrawal
- weed-relapse-prevention-plan
- weed-relapse-why-it-happens
- weed-ritual-replacement
- weed-ruined-relationships
- weed-social-media-triggers-quit
Cite This Study
https://rethinkthc.com/research/RTHC-06287APA
Dadiotis, Evangelos; Mpakaoukas, Sotiris; Mitsis, Vangelis; Melliou, Eleni; Magiatis, Prokopios. (2025). Identification of Three Novel Tetrahydrocannabinol Analogs in the European Market.. Drug testing and analysis, 17(9), 1594-1600. https://doi.org/10.1002/dta.3866
MLA
Dadiotis, Evangelos, et al. "Identification of Three Novel Tetrahydrocannabinol Analogs in the European Market.." Drug testing and analysis, 2025. https://doi.org/10.1002/dta.3866
RethinkTHC
RethinkTHC Research Database. "Identification of Three Novel Tetrahydrocannabinol Analogs i..." RTHC-06287. Retrieved from https://rethinkthc.com/research/dadiotis-2025-identification-of-three-novel
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.